These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32153788)

  • 1. Body composition in heart failure and the impact of cardiac resynchronisation therapy: a proof-of-concept study.
    McAloon CJ; Hyndman S; Ansell V; O'Hare P; Randeva H; Osman F
    Open Heart; 2020; 7(1):e001105. PubMed ID: 32153788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of cardiac magnetic resonance imaging, echocardiography and electrocardiography for the prediction of clinical response and long-term survival following cardiac resynchronisation therapy.
    Ellims AH; Pfluger H; Elsik M; Butler MJ; Hare JL; Taylor AJ
    Int J Cardiovasc Imaging; 2013 Aug; 29(6):1303-11. PubMed ID: 23568562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longer right to left ventricular activation delay at cardiac resynchronization therapy implantation is associated with improved clinical outcome in left bundle branch block patients.
    Kosztin A; Kutyifa V; Nagy VK; Geller L; Zima E; Molnar L; Szilagyi S; Ozcan EE; Szeplaki G; Merkely B
    Europace; 2016 Apr; 18(4):550-9. PubMed ID: 26116830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mid-regional pro-atrial natriuretic peptide to predict clinical course in heart failure patients undergoing cardiac resynchronization therapy.
    Arrigo M; Truong QA; Szymonifka J; Rivas-Lasarte M; Tolppanen H; Sadoune M; Gayat E; Cohen-Solal A; Ruschitzka F; Januzzi JL; Singh JP; Mebazaa A
    Europace; 2017 Nov; 19(11):1848-1854. PubMed ID: 28096288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of clinical outcome in patients treated with cardiac resynchronization therapy - the role of NT-ProBNP and a combined response score.
    Bakos Z; Chatterjee NC; Reitan C; Singh JP; Borgquist R
    BMC Cardiovasc Disord; 2018 Apr; 18(1):70. PubMed ID: 29699498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Usefulness of N-terminal Prohormone of Brain Natriuretic Peptide and High Sensitivity Troponin T in Patients with Heart Failure Undergoing Cardiac Resynchronization Therapy.
    Debska-Kozlowska A; Ksiazczyk M; Warchol I; Lubinski A
    Curr Pharm Des; 2019; 25(14):1671-1678. PubMed ID: 31223080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of NT-pro BNP monitoring to identify echocardiographic responders following cardiac resynchronization therapy.
    Magne J; Dubois M; Champagne J; Dumesnil JG; Pibarot P; Philippon F; O'Hara G; Sénéchal M
    Cardiovasc Ultrasound; 2009 Aug; 7():39. PubMed ID: 19695099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac resynchronization therapy in patients with heart failure and moderately reduced ejection fraction: Could it trigger a super-response?
    Tawfik Ghanem M; Allam LE; Samir Ahmed R
    Indian Heart J; 2019; 71(3):229-234. PubMed ID: 31543195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification of ventricular resynchronization reserve by radionuclide phase analysis in heart failure patients: a prospective long-term study.
    Dauphin R; Nonin E; Bontemps L; Vincent M; Pinel A; Bonijoly S; Barborier D; Ribier A; Fernandes CM; Bert-Marcaz P; Itti R; Chevalier P
    Circ Cardiovasc Imaging; 2011 Mar; 4(2):114-21. PubMed ID: 21239562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of left ventricular reverse remodeling and brain natriuretic peptide level at one year after cardiac resynchronization therapy predicts long-term clinical outcome.
    Roubicek T; Stros J; Kucera P; Nedbal P; Cerny J; Polasek R; Wichterle D
    PLoS One; 2019; 14(7):e0219966. PubMed ID: 31314790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the effects of cardiac resynchronization therapy on pathophysiological pathways of heart failure using surrogate biomarkers.
    Sunman H; Özkan A; Yorgun H; Canpolat U; Karabulut E; Bayrak T; Kaya EB; Tokgözoğlu L; Özer N; Özkara A; Aytemir K; Oto A
    Cardiol J; 2018; 25(1):42-51. PubMed ID: 28980281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High sensitivity C-reactive protein predicts nonresponders and cardiac deaths in severe heart failure patients after CRT implantation.
    Kamioka M; Suzuki H; Yamada S; Kamiyama Y; Saitoh S; Takeishi Y
    Int Heart J; 2012; 53(5):306-12. PubMed ID: 23038092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete left bundle branch block and smaller left atrium are predictors of response to cardiac resynchronization therapy in advanced heart failure.
    Imamura T; Kinugawa K; Nitta D; Komuro I
    Circ J; 2015; 79(11):2414-21. PubMed ID: 26376671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of cardiac resynchronization therapy on inflammatory biomarkers and cardiac remodeling: The paradox of functional and echocardiographic response.
    Almeida-Morais L; Abreu A; Oliveira M; Silva Cunha P; Rodrigues I; Portugal G; Rio P; Soares R; Mota Carmo M; Cruz Ferreira R
    Rev Port Cardiol (Engl Ed); 2018 Feb; 37(2):105-113. PubMed ID: 29503051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and classic echocardiographic features of patients with, and without, left ventricle reverse remodeling following the introduction of cardiac resynchronization therapy.
    Wiliński J; Czarnecka D; Wojciechowska W; Kloch-Badełek M; Jastrzębski M; Bacior B; Sondej T; Kusak P; Przybyła A; Kawecka-Jaszcz K
    Cardiol J; 2011; 18(2):157-64. PubMed ID: 21432822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Effect of Different Optimizing Methods for Cardiac Resynchronization Therapy in Patients with Heart Failure: A Randomized and Controlled Pilot Study.
    Zhang Y; Xing Q; Zhang JH; Jiang WF; Qin M; Liu X
    Cardiology; 2019; 142(3):158-166. PubMed ID: 31189165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac resynchronization therapy in pacemaker-dependent patients with left ventricular dysfunction.
    Gierula J; Cubbon RM; Jamil HA; Byrom R; Baxter PD; Pavitt S; Gilthorpe MS; Hewison J; Kearney MT; Witte KK
    Europace; 2013 Nov; 15(11):1609-14. PubMed ID: 23736807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterisation of circulating biomarkers before and after cardiac resynchronisation therapy and their role in predicting CRT response: the COVERT-HF study.
    McAloon CJ; Barwari T; Hu J; Hamborg T; Nevill A; Hyndman S; Ansell V; Musa A; Jones J; Goodby J; Banerjee P; O'Hare P; Mayr M; Randeva H; Osman F
    Open Heart; 2018; 5(2):e000899. PubMed ID: 30364565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility, safety, and mid-term efficacy of cardiac resynchronization therapy in patients with severe heart failure and ventricular conduction delay: Chulalongkorn experience.
    Sunsaneewitayakul B; Sitthisook S; Sangwatanaroj S; Prechawat S; Songmuang SB
    J Med Assoc Thai; 2007 Jul; 90(7):1458-66. PubMed ID: 17710992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of Left Ventricular Size and Sex on Outcome of Cardiac Resynchronization Therapy Among Patients With a Narrow QRS Duration in the EchoCRT Trial.
    Varma N; Sogaard P; Bax JJ; Abraham WT; Borer JS; Dickstein K; Singh JP; Gras D; Holzmeister J; Brugada J; Ruschitzka F
    J Am Heart Assoc; 2018 May; 7(11):. PubMed ID: 29807890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.